Bioqual, Inc. Reports Earnings Results for the Third Quarter Ended February 29, 2020
April 21, 2020 at 02:58 pm EDT
Share
Bioqual, Inc. announced earnings results for the third quarter ended February 29, 2020. For the third quarter, the company announced sales was USD 11.593 million compared to USD 9.908 million a year ago. Net income was USD 720,406 compared to USD 465,774 a year ago. Basic earnings per share was USD 0.81 compared to USD 0.52 a year ago. For the nine months, sales was USD 32.884 million compared to USD 27.922 million a year ago. Net income was USD 2.936 million compared to USD 1.667 million a year ago. Basic earnings per share was USD 3.29 compared to USD 1.87 a year ago.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
